Professor Kevin Harrington
Kevin Harrington is professor of biological cancer therapies at the Institute of Cancer Research, and a consultant clinical oncologist at the Royal Marsden NHS Foundation, in London, UK. He is also joint head of the division of Radiotherapy and Imaging at the Royal Marsden. In addition to expertise in the use of radiotherapy and chemoradiotherapy, he is an authority on drug treatment of patients with relapsed and metastatic head and neck cancer.
Professor Harrington studied medicine at St Bartholomew's Hospital, London, completed a PhD at the Hammersmith Hospital, London, and conducted post-doctoral research in molecular medicine at the Mayo Clinic, Minnesota. His current research is concentrated in two main areas: the use of immunomodulatory microbial agents as anti-cancer therapeutics, and the development of new drugs to improve the activity of radiation against cancer cells. He has published more than 400 articles on cancer treatment, and his work has been featured in newspaper and television reports.
Professor Reinhard Dummer
Reinhard Dummer is professor and Vice-chairman of the department of dermatology at the University Hospital of Zürich, Switzerland, and heads the Skin Cancer unit and Dermatology Clinical Trial unit there. He is board-certified in allergology, clinical immunology, dermatology and dermatopathology and is an authority on cutaneous oncology.
Professor Dummer began his medical education in hematology and oncology before successfully completing his dermatology residency in Würzburg, Germany, and in Zürich. His principal research interests are molecular biology, immunology and immunotherapy of cutaneous malignancies, including cutaneous lymphomas and melanomas. He has published more than 600 papers and been a member (and frequently the president) of numerous medical and academic groups including the International Society for Cutaneous Lymphomas, the Melanoma Project Group of the Swiss Institute for Applied Cancer Research, the European Society for Dermatological Research (ESDR), the European Society for Medical Oncology (ESMO) Cancer Research Faculty Group, and the ESMO Educational Committee.
Professor George Coukos
George Coukos is professor at the University of Lausanne, Switzerland, director of the department of oncology at the University Hospitals of Canton Vaud (CHUV), director of the service of developmental therapeutics, and director of the Ludwig Centre at the University of Lausanne.
Professor Coukos received his medical degree and PhD from the University Hospital of Modena, Italy, and the University of Pennsylvania, USA. His main research interests are tumor immunology and immunotherapy and he is a globally recognized leader in ovarian cancer immunotherapy with extensive experience in designing and conducting immunotherapy clinical trials. Professor Coukos is a member of many professional societies, has more than 200 significant publications, and has received more than 20 awards for his work. He was named a Top Doctor for Cancer in America from 2008-2012.
Former director and Professor emeritus at the Biozentrum, University of Basel and former director at the Max-Planck-Institute for Biochemistry in Martinsried, Germany. He is a leader in the field of cell cycle and cancer and one of Europe’s top cited cell biologists.
Professor emeritus at the Biozentrum, University of Basel and Professor at the University of Namur, Belgium. As a co-discoverer of the bacterial type 3 secretion system, he has more than 30 years of experience on the pathogenesis of Yersinia enterocolitica and other Gram-negative bacteria. He is a renowned expert in the field of bacterial pathogenesis and highly cited author of many research publications.
He has a longstanding track record in the field of tumor biology and translational cancer research. In particular, he has developed and tested various anti-angiogenic agents for cancer therapy, he has generated a variety of preclinical cancer models to study the molecular mechanisms underlying malignant tumor progression and to experimentally test novel therapeutic regimen in a preclinical setting, and he has discovered several novel molecular pathways and master switches critical for the metastatic dissemination of malignant cancer cells.